CD20 Antibody Global Market Report 2025

The CD20 antibody market size has grown rapidly in recent years. It will grow from $9.94 billion in 2024 to $10.99 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to the increasing prevalence of B-cell malignancies, the rising incidence of autoimmune diseases, the growing demand for targeted therapies, the increasing approvals of biosimilars, rising healthcare expenditure, improvements in healthcare infrastructure, and greater awareness of the benefits of immunotherapy.

The CD20 antibody market size is expected to see rapid growth in the next few years. It will grow to $16.24 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to the rising demand for advanced cancer immunotherapies, the increasing prevalence of autoimmune disorders, the growing adoption of biosimilar CD20 antibodies, the expanding applications in combination therapies, the increasing investment in biopharmaceutical research, and the growing awareness of personalized medicine. Key trends include the development of next-generation CD20 antibodies, advancements in antibody-drug conjugates, the integration of artificial intelligence in antibody design, improvements in bispecific antibody technology, the rise of CAR-T cell therapies targeting CD20, the adoption of nanotechnology for enhanced delivery, and advancements in high-throughput screening methods.

The growing prevalence of B-cell malignancies is anticipated to drive the expansion of the CD20 antibody market in the coming years. B-cell malignancies refer to the increasing incidence of cancers affecting B cells, a type of white blood cell crucial to the immune response. Various factors contribute to this rise, including an aging population, genetic predispositions, environmental exposures, lifestyle changes, advancements in detection methods, and alterations in the immune system. CD20 antibodies, such as rituximab, play a critical role in targeting and eliminating malignant B-cells in conditions such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, thereby improving treatment outcomes. For instance, a 2024 report by the American College of Cardiology, a US-based nonprofit medical association, estimates that in 2025, approximately 80,350 individuals (45,140 males and 35,210 females), including both adults and children, will be diagnosed with non-Hodgkin lymphoma (NHL). Furthermore, around 19,390 people (11,060 males and 8,330 females) are projected to succumb to this cancer. As a result, the increasing occurrence of B-cell malignancies is propelling the expansion of the CD20 antibody market.

Leading companies in the CD20 antibody market are prioritizing technological advancements such as biosimilars to improve treatment accessibility, lower healthcare costs, and meet the growing need for affordable and effective therapies for B-cell malignancies and autoimmune diseases. Biosimilars are biologic medical products that closely resemble an already approved reference product without any significant differences in safety, purity, or efficacy. For example, in July 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, announced that it had received a complete response letter (CRL) from the US Food and Drug Administration (USFDA) for its rituximab biosimilar candidate. The company intends to collaborate with the USFDA to resolve all concerns within the designated timeframe, aiming to introduce the biosimilar rituximab to patients in the United States. Rituximab biosimilar functions by targeting the CD20 protein on the surface of B-cells, triggering a response that leads to the destruction of these abnormal or overactive B-cells.

In October 2024, GSK plc, a UK-based biopharmaceutical and biotechnology company, acquired CMG1A46, a dual CD19 and CD20-targeted T cell-engager (TCE) currently in clinical development, from Chimagen Biosciences for an undisclosed sum. Through this acquisition, GSK aims to develop and commercialize CMG1A46, focusing on B cell-driven autoimmune diseases such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with the potential for expansion into related autoimmune conditions. Chimagen Biosciences, a China-based clinical-stage biotechnology firm, specializes in discovering and developing novel multi-specific T cell-engagers and NK cell-engagers.

Major players in the CD20 antibody market are F Hoffmann-La Roche AG, Merck & Co Inc, Thermo Fisher Scientific Inc, Novartis AG, GlaxoSmithKline plc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Biogen Inc, Genentech Inc, Bio-Rad Laboratories Inc, Genmab A/S, Bio-Techne, LFB Biotechnologies SA, Abcam Limited, Sino Biological Inc, Mylan NV, Immunomedics Inc, Spectrum Pharmaceuticals Inc, MyBiosource Inc, IGM Biosciences Inc, and TG Therapeutics Inc.

North America was the largest region in the CD20 antibody market in 2024. The regions covered in CD20 antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the CD20 antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

CD20 antibodies are monoclonal antibodies that specifically target CD20, a protein present on the surface of B cells, a type of white blood cell involved in the immune response. These antibodies are primarily used to treat conditions associated with abnormal B-cell function, including cancers and autoimmune diseases. Their primary role is to bind to the CD20 protein on B cells and initiate their destruction.

The primary end users of CD20 antibodies include hospitals, specialty clinics, ambulatory surgical centers, and others. These antibodies are utilized in various applications such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), western blot, immunoprecipitation, and immunofluorescence. CD20 antibodies are categorized into two main types, monoclonal and polyclonal antibodies. Monoclonal antibodies are laboratory-engineered proteins designed to bind to specific targets, such as the CD19 antigen found on B cells.

The CD-20 antibody market research report is one of a series of new reports that provides CD-20 antibody market statistics, including CD-20 antibody industry global market size, regional shares, competitors with a CD-20 antibody market share, detailed CD-20 antibody market segments, market trends and opportunities, and any further data you may need to thrive in the CD-20 antibody industry. This CD-20 antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The CD20 antibody market consists of sales of rituximab, obinutuzumab, and ofatumumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.